VIDEO: Adding immunotherapy for some thyroid cancers shows 'promising preliminary results'
Click Here to Manage Email Alerts
In this video, Jonathan Wadsley, MA, MRCP, FRCR, discussed a symposium on immunotherapy titled "Tumor/immune environment in thyroid cancer: Its exploitation in immunotherapy" given at the American Thyroid Association Annual Meeting.
"In many other cancers, immunotherapy has a big place in standard of care," Wadsley, a consultant clinical oncologist at Weston Park Hospital in Sheffield, U.K., said, adding that research presented at ATA indicated it may be of benefit for patients with more aggressive thyroid cancers, anaplastic thyroid cancers and/or BRAF mutations.
Regarding the standard-of-care combination BRAF/MEK inhibitor approach, Wadsley said, “the possibility of adding immunotherapy and checkpoint inhibitor into that combination is being investigated with quite promising preliminary results."
Collapse
Healio Interviews
Click Here to Manage Email Alerts